Viatris Secures Global Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe
Viatris Signs Exclusive Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe PITTSBURGH, Oct. 16, 2024 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) has reached an exclusive licensing agreement with…
Regional Study Shows Blood Biomarkers Can Predict Brain Amyloid Beta Accumulation
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and the Usuki City Medical Association have demonstrated that blood biomarkers can effectively predict amyloid beta (Aβ) accumulation in the brain, a major…
Shionogi Showcases Global Study on Cefiderocol Highlighting High Clinical Response in Critically Ill Patients
Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for…
WuXi Biologics Earns Fourth Consecutive ESG Corporate Platinum Award from The Asset
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), announced its fourth consecutive Platinum Award from The Asset ESG (Environmental, Social, and Governance)…
BeiGene Showcases Waldenström’s Macroglobulinemia Advances at IWWM 2024
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the…
Alnylam Submits EMA Application for Vutrisiran in ATTR Amyloidosis Treatment
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II…
Sanofi and Orano Collaborate to Advance Next-Generation Radioligand Therapies
Sanofi and Orano Partner to Develop Next-Generation Radioligand Therapies Paris, October 17, 2024 – Sanofi and Orano Med, a subsidiary of the Orano Group and a leader in targeted alpha…
AstraZeneca Pushes Forward Infectious Disease Protection Science at IDWeek 2024
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial…
Etcembly and University of Surrey Launch Study on Next-Gen Cancer Treatments from Survivors
Etcembly and University of Surrey Launch Study to Transform Cancer Treatment British techbio innovator Etcembly is collaborating with researchers from the University of Surrey to launch a groundbreaking study aimed…
Merck’s CAPVAXIVE™ Vaccine Shows Positive Immune Response in Adults at Risk for Pneumococcal Disease
STRIDE-8 Study Results Highlight CAPVAXIVE’s Efficacy in Pneumococcal Disease Prevention CAPVAXIVE Demonstrates Strong Immune Response and Coverage Against Major Serotypes RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside…
ViiV Healthcare Reports Over 99% Effectiveness for Apretude in Real-World Studies at IDWeek 2024
ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has…
FDA Grants Priority Review for Gepotidacin to Treat Uncomplicated UTIs in Women and Adolescents
GSK’s Gepotidacin Accepted for FDA Priority Review to Treat Uncomplicated UTIs GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug…